This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cyanide poisoning

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Cyanide is toxic by ingestion, inhalation and skin contact. It is present in some insecticides, rodenticides, metal polishes, electroplating solutions and fumigants, and is used in a variety of metallurgical processes. Apricot kernels contain cyanogenic glycosides which are cleaved by gastrointestinal flora to liberate hydrogen cyanide.

Cyanide is used widely in the chemical industry, in laboratories and in photographic processing. Burning plastic tends to liberate hydrogen cyanide.

Cyanide reversibly inhibits cellular oxidising enzymes which contain ferric iron such as cytochrome oxidase. This has the effect of uncoupling oxidative phosphorylation. As a result, a range of clinical features are produced which are primarily due to tissue hypoxia.

The ingestion of 50 mg of hydrogen cyanide, or 200-500 mg of its salts, is likely to be fatal. Poisoning is enhanced by an empty stomach and high gastric acidity. A full stomach may delay symptoms for up to 4 hours. Inhalation of hydrogen cyanide may produce symptoms within seconds, and death within minutes.

The measurement of blood levels has little clinical significance but may be of forensic importance. Generally, serum levels greater than 1 mg/litre are fatal. Smokers may have incidental serum cyanide levels of 0.1 mg/litre.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.